Alembic Pharmaceuticals Limited has informed the Exchange that it has received Establishment Inspection Report (EIR) for its API-III Facility at Karakhadi
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received the Establishment Inspection Report (EIR) from the US FDA for its API-III manufacturing facility at Karakhadi, Vadodara. The EIR closes out the USFDA inspection that was conducted at the facility from March 17 to March 21, 2025. Receiving an EIR indicates the inspection has been successfully closed by the regulator without any outstanding compliance concerns. The company had earlier intimated the exchanges on March 21, 2025, about the successful completion of this inspection.
Positive for shareholders — the EIR confirms that the API-III facility remains compliant with USFDA standards, which is important for Alembic's US business and future product approvals/supplies from this plant. This reduces regulatory overhang and supports continuity of exports from the Karakhadi facility.